Evaluation of chronic oral toxicity and carcinogenic potential of lornoxicam in rats

Food and Chemical Toxicology

Volumn 35, Issue 9, 1997, Pages 909-922

  Pohlmeyer Esch, G ^a   Mehdi, N ^a,b   Clarke, D ^a   Radhofer Welte, S ^a  

^a Nycomed Holdings AS   (Austria)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LORNOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT;

ANEMIA; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CHRONIC TOXICITY; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; ELECTROCARDIOGRAM; FEMALE; KIDNEY PAPILLA NECROSIS; MALE; MORTALITY; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; TOXICOKINETICS; WEIGHT GAIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; KIDNEY; MALE; NEOPLASMS, EXPERIMENTAL; PIROXICAM; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS;

ANIMALIA;

EID: 0030722885     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(97)00062-8     Document Type: Article

References (39)

1. Bach P. H., Grasso P., Molland E. A. and Bridges J. W. (1983) Changes in medullary glycosaminoglycan histochemistry and microvascular filling during the development of 2-bromethanamine hydrobromide-induced renal papillary necrosis. Toxicology and Applied Pharmacology 69, 333-344.
2. Balfour J. A., Fitton A. and Barradell L. B. (1996) Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 51, 639-657.
3. Berry H. and Ollier S. (1990) Lornoxicam in clinical practice Postgraduate Medical Journal 66 (Suppl. 4), S41-S45.
4. Bertram T. A. (1991) Gastrointestinal tract: mechanisms of gastrointestinal toxicity. In Handbook of Toxicologic Pathology. Edited by W. M. Haschek and C. G. Rousseaux. pp. 214-220. Academic Press, San Diego, CA.
5. Bonnabry P., Leemann T. and Dayer P. (1996) Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. European Journal of Clinical Pharmacology 49, 305-308.
6. Boudinot S. G., Funderburg E. D. and Boudinot F. D. (1993) Effects of age on the pharmacokinetics of piroxicam in rats. Journal of Pharmaceutical Science 82, 254-257.
7. Brooks P. M. and Day R. O. (1991) Nonsteroidal antiinflammatory drugs - differences and similarities. New England Journal of Medicine 324, 1716-1725.
8. Clive D. M. and Stoff J. S. (1984) Renal syndromes associated with nonsteroidal antiinflammatory drugs. New England Journal of Medicine 310, 563-572.
9. Davenport H. W. (1964) Gastric mucosal injury by fatty and acetylsalicylic acids. Gastroenterology 46, 245-253.
10. Faccini J. M. (1982) A perspective on the pathology and cytochemistry of renal lesions. In Nephrotoxicity Assessment and Pathogenesis. Edited by P. H. Bach, F. W. Bonner, J. W. Bridges and E.D. Lock. pp. 82-97. John Wiley & Sons, Chichester.
11. Ferreira S. H., Moncada S. and Vane J. R. (1971) Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature 231, 237-239.
12. Fries J. F., Miller S. R., Spitz P. W., Williams C. A., Hubert H. B. and Bloch D. A. (1989) Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 96, 647-655.
13. Gerber J. G., Olson R. D. and Nies A. S. (1981) Interrelationship between prostaglandins and renin release. Kidney International 19, 816-821.
14. Gross P. A., Schrier R. W. and Anderson R. J. (1981) Prostaglandins and water metabolism: a review with emphasis on in vivo studies. Kidney International 19, 839-850.
15. Hitzenberger G., Radhofer-Welte S., Takacs F. and Rosenow D. (1990) Pharmacokinetics in man. Postgraduate Medical Journal 66 (Suppl. 4), S22-S26.
16. Kincaid-Smith P., Saker B. M., McKenzie I. F. C. and Muriden K. D. (1968) Lesions in the blood supply of the papilla in experimental analgesic nephropathy, Medical Journal of Australia 1, 203-206.
17. Kirschenbaum M. A., White N., Stein J. H. and Ferris T. F. (1974) Redistribution of renal cortical blood flow during inhibition of prostaglandin synthesis. American Journal of Physiology 227, 801-805.
18. Kokko J. P. (1981) Effect of prostaglandins on renal epithelial electrolyte transport. Kidney International 19, 791-796.
19. Levenson D. J., Simmons C. E., Jr and Brenner B. M. (1982) Arachidonic acid metabolism, prostaglandins and the kidney. American Journal of Medicine 72, 354-374.
20. Lewis G. P. (1977) Prostaglandin in inflammation. Journal of the Reticuloendothelial Society 22, 389-402.
21. Lifschitz M. D. (1981) Prostaglandins and renal blood flow: in vivo studies. Kidney International 19, 781-785.
22. Maekawa A. and Hayashi Y. (1992) Neoplastic lesions of the testis. In Pathobiology of the Ageing Rat. Vol. 1. Edited by U. Mohr, D. L. Dungworth and C. C. Capen. pp. 413-418. ILSI Press, Washington.
23. Main I. H. M. and Whittle B. J. R. (1975) Investigation of the vasodilator and antisecretory role of prostaglandins in the rat gastric mucosa using non-steroidal anti-inflammatory drugs. British Journal of Pharmacology 53, 217-224.
24. Molland E. A. (1978) Experimental renal papillary necrosis. Kidney International 13, 5-14.
25. Patrono C. and Dunn M. J. (1987) The clinical significance of inhibition of renal prostaglandin synthesis. Kidney International 32, 1-12.
26. Peto R., Pike M. C., Day N. E., Gray R. G., Lee P. N., Parish S., Peto J., Richards S. and Wahrendorf J. (1980) Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. IARC Monographs, Suppl. 2 (Annex), 311-426.
27. Pruss T. P., Stroissnig H., Radhofer-Welte S., Wendtlandt W., Mehdi N., Takacs F. and Fellier H. (1990) Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgraduate Medical Journal 66 (Suppl. 4), S18-S21.
28. Roskos L. K. and Boudinot F. D. (1990) Effects of dose and sex on the pharmacokinetics of piroxicam in the rat. Biopharmaceutics and Drug Disposition 11, 215-225.
29. Schnermann J. and Briggs J. P. (1981) Participation of renal cortical prostaglandins in the regulation of glomerular filtration rate. Kidney International 19, 802-815.
30. Schwartzman M., Carroll M. A., Ibraham N. G., Ferreri N. R., Songu-Mize E. and McGiff J. C. (1985) Renal arachidonic acid metabolism. The third pathway. Hypertension 7, 136-144.
31. Shriver D. A., White C. B., Sandor A. and Rosenthale M. E. (1975) A profile of the rat gastrointestinal toxicity of drugs used to treat inflammatory diseases. Toxicology and Applied Pharmacology 32, 73-83.
32. Smith D. A. (1991) Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metabolism Reviews 23, 355-373.
33. Smith J. B. and Willis A. L. (1971) Aspirin selectively inhibits prostaglandin production in human platelets. Nature 231, 235-237.
34. Soll A. H. (1990) Pathogenesis of peptic ulcer and implications for therapy. New England Journal of Medicine 322, 909-916.
35. Vane J. R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 231, 232-235.
36. Weite S. and Ferber H. P. (1987) Toxicokinetic investigations on the NSAID chlortenoxicam determined by HPLC. Int. Symposium on Pharmaceutical Analysis. Barcelona, Spain.
37. Whelton A., Stout R. L., Spilman P. S. and Klassen D. K. (1990) Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. Annals of Internal Medicine 112, 568-576.
38. Whittle B. J. R., Higgs G. A., Eakins K. E., Moncada S. and Vane J. R. (1980) Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 284, 271-273.
39. Zhao J., Leemann T. and Dayer P. (1992) In vitro oxidation of oxicam NSAIDs by human liver cytochrome P-450. Life Sciences 51, 575-581.